Treatment of patients with Philadelphia chromosome-positive B-cell acute lymphoblastic
leukemia (Ph+ B-ALL) with tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib …

Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) is a recently
described B-cell precursor ALL with a gene expression profile and a high frequency of IKZF1 …

Simple Summary Outcome of patients with Philadelphia-chromosome positive acute
lymphoblastic leukemia (Ph+ ALL) dramatically improved during the past 20 years with the …

Background Philadelphia chromosome–like acute lymphoblastic leukemia (Ph-like ALL) is
characterized by a gene-expression profile similar to that of BCR–ABL1–positive ALL …

The Philadelphia (Ph) chromosome, a short chromosome 22, is the most frequent
cytogenetic abnormality in adult patients with acute lymphoblastic leukemia (ALL). It occurs …

The t (9; 22)(q34; q11) or Philadelphia chromosome creates a BCR–ABL1 fusion gene
encoding for a chimeric BCR–ABL1 protein. It is present in 3–4% of pediatric acute …

Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a high-risk
subtype characterized by genomic alterations that activate cytokine receptor and kinase …

Opinion statement With the introduction of tyrosine kinase inhibitors (TKIs) in the
management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ …

Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) represents the
most common cytogenetic abnormality in adult ALL. It is found in 15% to 30% of patients …

Early recognition of Philadelphia-like (Ph-like) acute lymphoblastic leukemia (ALL) cases
could impact on the management and outcome of this subset of B-lineage ALL. In order to …